Business Wire

PA-BOOMI

Share
Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation

Boomi™, the intelligent integration and automation leader, today announced that the six inaugural Boomi AI Agents recently unveiled at the company’s Boomi World event will be available in the Boomi Enterprise Platform as part of existing customer licenses, enabling customers to fully harness AI-powered capabilities for unparalleled innovation. These agents include:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611275117/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation (Graphic: Business Wire)

  • Boomi Answers: Save time spent searching through user community discussions and articles. Simply ask questions about Boomi and get the most useful answer from over 240K community users.
  • Boomi DataDetective: Stay on top of data privacy, protect sensitive information with AI-powered data classification, and track where data is being moved.
  • Boomi DesignGen: Ask GenAI to design integration processes based on 200M+ common patterns and best practices.
  • Boomi GPT: Describe integration and automation needs using natural language and have conversations with the Boomi Enterprise Platform to get more meaningful results, faster.
  • Boomi Pathfinder: Provide patented suggestions on the next best steps to take when building integration processes.
  • Boomi Scribe: Skip manually writing documentation about existing and AI-generated integration processes, and let GenAI handle the busywork of detailing process descriptions and business use cases.

To accelerate innovation, Boomi recently introduced the Boomi AI Agent Framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.

“AI agents are revolutionizing industries by automating repetitive tasks, analyzing vast datasets, and offering personalized customer service,” said Steve Lucas, CEO at Boomi. “Data is the lifeblood of AI, especially with pre-trained transformers and LLM's. Boomi delivers that data, and the Boomi AI Agents improve efficiency, accuracy, and scalability for organizations by operating around the clock with high precision, enhancing decision-making, supporting human workers, and driving innovation. These capabilities lead to increased productivity and cost savings, making them invaluable assets for organizations to maintain a competitive edge."

AI agents are sophisticated software entities designed with a specific scope and personality, enabling them to function within predefined parameters and exhibit particular behaviors. Operating autonomously, they can make decisions using advanced AI-based reasoning algorithms, and can independently take actions to achieve their objectives. AI agents can function with or without human intervention. Additionally, AI agents can either work independently or collaborate with other AI agents, depending on the requirements of the task at hand. This flexibility and autonomy make AI agents highly versatile and capable of performing a wide range of functions across various applications, improving decision-making processes with data-driven insights, and powering innovation by enabling new applications and services.

The Boomi AI Agent Framework includes three types of agents running on the Boomi Enterprise Platform:

Boomi AI Agents

Boomi AI Agents provide AI-powered capabilities within the platform. These capabilities can be utilized through the Boomi GPT conversational user interface (CUI), via specialized GUI, in the process canvas, or via API.

Partner AI Agents

Partner AI agents are pluggable components that allow Boomi Enterprise Platform users to install and use best-of-breed AI functions from Boomi’s network of partners. These agents can be utilized in the same way as Boomi AI Agents, and allow rich capabilities to be incorporated from across the digital ecosystem. An example is the recently announced Boomi FinTalk powered by Vianai agent that allows business users to get detailed responses on financial information via Boomi GPT.

User-created AI Agents

User-created AI agents are developed using the Boomi Enterprise Platform, which provides all the necessary building blocks. Boomi’s connectivity and orchestration capabilities enable users to interact with selected models via API, access proprietary data sources, and automate actions through various applications. The Boomi platform’s process canvas allows the creation of sophisticated workflows to retrieve, combine, filter, and contextualize data, facilitating model prompting and techniques like RAG and fine-tuning. Boomi DataHub serves as an access point and repository for the agents’ knowledge base, while Boomi Flow and Boomi API Management offer human or machine interfaces to package these components into standalone AI agents.

Boomi AI Agents will be available with the July 2024 release of the Boomi Enterprise Platform. More information can be found here.

Additional Resources

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611275117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release

Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T

Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release

Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye